Targacept to Present at the Stifel Healthcare Conference 2013 Stifel Nicolaus 2013 Global Healthcare Conference Business Wire WINSTON-SALEM, N.C. -- September 5, 2013 Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel Boston on Thursday, September 12, 2013 at 8:35 a.m. Eastern Time. The presentation will be webcast and accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the event. About Targacept Targacept is developing an advanced clinical pipeline of NNR Therapeutics™ to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. Many diseases arise from abnormalities in signaling within and between the brain and other organ systems such as the bladder and the GI tract. Targacept’s NNR Therapeutics have the potential to normalize these signaling pathways to provide significant medical benefit. Targacept is dedicated to building health and restoring independence for patients. For more information, please visit www.targacept.com. TARGACEPT Building Health, Restoring Independence^® Contact: Targacept, Inc. Alan Musso, 336-480-2186 SVP, Finance and Administration and CFO firstname.lastname@example.org or Linnden Communications Michelle Linn, 508-362-3087 email@example.com
Targacept to Present at the Stifel Healthcare Conference 2013
Press spacebar to pause and continue. Press esc to stop.